RxDoctor Payments DataLook up a doctor →

Mackenzi Heaton

Nurse Practitioner · Spokane, WANPI 1811657034

Payments from drug & device makers

$11,520in general payments, 2019–2025

Across 411 payments — averaging $28.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$832
  • Pfizer$643
  • Novartis$602
  • Johnson & Johnson$577
  • Daiichi Sankyo Inc.$557
  • AstraZeneca$554
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$10,71093%
  • Education$8097%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.34$832
Pfizer47$643
Novartis34$602
Johnson & Johnson(2 entities)20$577
Daiichi Sankyo Inc.6$557
AstraZeneca13$554
Bristol Myers Squibb34$542
Lilly USA, LLC12$389
Merck12$336
Sanofi9$335
Jazz Pharmaceuticals Inc.6$317
GSK7$316
Takeda Pharmaceuticals U.S.A., Inc.7$311
Genentech USA, Inc.15$297
Exelixis Inc.3$277
AbbVie7$268
Janssen Scientific Affairs, LLC2$262
Seagen Inc.9$251
Gilead(2 entities)6$232
Bayer6$227
Eisai Inc.11$223
Astellas Pharma US Inc4$211
G1 Therapeutics, Inc.4$186
Amgen9$186
Boehringer Ingelheim7$181
Incyte Corporation9$181
Sanofi-aventis U.S. LLC3$173
Agios Pharmaceuticals, Inc.2$143
Beigene USA, Inc.4$128
Pharmaessentia USA Corporation1$123
AVEO Pharmaceuticals, Inc.4$116
Tempus AI, Inc3$114
Myriad Genetic Laboratories, Inc.2$104
Regeneron Healthcare Solutions, Inc.3$98
Pharmacyclics LLC, An Abbvie Company4$94
Array Biopharma Inc4$86
Sobi, Inc3$86
CTI Biopharma Corp.3$81
EMD Serono, Inc.3$72
Alnylam Pharmaceuticals Inc.4$71
Tersera Therapeutics LLC3$66
Acrotech Biopharma Inc.3$55
Pharmacosmos Therapeutics Inc.2$55
Taiho Oncology, Inc.2$51
Servier Pharmaceuticals LLC2$43
Adaptive Biotechnologies Corporation2$41
Sumitomo Pharma America, Inc.2$40
Morphosys, US Inc.2$37
Fresenius Kabi USA, LLC2$36
Heron Therapeutics, Inc.2$36
Immunocore Limited1$33
EUSA Pharma (US) LLC2$33
Stryker1$31
Stemline Therapeutics Inc.1$25
Accord Healthcare, Inc.1$25
Deciphera Pharmaceuticals Inc.1$24
Foundation Medicine, Inc.1$22
Fennec Pharmaceuticals, Inc.1$19
Coherus Oncology, Inc.1$18
Telix Pharmaceuticals1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,520 in reported general payments places this provider in the 95th percentile of 2,466 nurse practitioner providers in Washington.

See all nurse practitioner providers in Washington

Medicare billing

Part B allowed, 2024
$21,062
Medicare patients
36
Services billed
856

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prochlorperazine Maleate16$128

Paid to pharmacies, not to this prescriber.

Other nurse practitioner in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →